| 1 |
33199443 | EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. | 2021 Sep |
2 |
| 2 |
34323910 | Gene-editing by CRISPR-Cas9 in combination with anthracycline therapy via tumor microenvironment-switchable, EGFR-targeted, and nucleus-directed nanoparticles for head and neck cancer suppression. | 2021 Sep 1 |
2 |
| 3 |
32923587 | Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy. | 2020 Jul |
1 |
| 4 |
27045718 | [Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients]. | 2016 Mar 29 |
3 |
| 5 |
25844392 | Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole. | 2014 Apr 9 |
2 |
| 6 |
23584895 | Diamond-lipid hybrids enhance chemotherapeutic tolerance and mediate tumor regression. | 2013 Jul 12 |
1 |
| 7 |
19480561 | Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition. | 2009 Jul |
3 |
| 8 |
16357174 | Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. | 2005 Dec 15 |
1 |
| 9 |
7847819 | Effects of cytostatic agents on the expression of epidermal growth factor receptor in ovarian cancer cells. | 1994 Sep-Oct |
2 |